未知生产厂商
AGX101 is a TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) designed to target TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach aims to address both the tumor cells and the supporting vasculature.
Unresectable, locally advanced or metastatic solid tumors (advanced solid tumors).
